A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

NCT04200404 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Refractory Solid Tumors

Interventions

DRUG: CS1001
DRUG: Regorafenib

Sponsor

CStone Pharmaceuticals

Collaborators

[object Object]